01 June 2006

AGM Statement

“The Group has continued to take important strides forward over the past twelve months. The major phase of investment has been completed and Cyprotex is now setting international standards in high throughput ADMET screening. High levels of automation and proprietary technologies provide exceptional opportunities for our shareholders, the benefits of which we expect to be realised in the coming year.

“Recent announcements regarding the significant expansion of the Group’s senior sales force in the US and contract successes reflect both the confidence of our management and our further evolution as a trusted service partner in the world of international drug discovery.

“Additional representation at Board level has been made during the period to fully meet the requirements of a growing and ambitious company in the global marketplace. We look forward with confidence to a productive year ahead”

The presentation given this morning to shareholders is available on the Company’s website: www.cyprotex.com

For further information:

Cyprotex PLC
Robert Morrison Atwater,Chairman and Chief Executive Officer
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Code Securities Limited
Chris Collins, Corporate Finance
Tel: +44 (0)20 7776 1200
cic@codesecurities.com
www.codesecurities.com

Media Enquires:
Abchurch
Heather Salmond/Georgina Bonham
Tel: +44 (0)20 7398 7700
heather.salmond@abchurch-group.com
www.abchurch-group.com